{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sinha A"],"funding":["Congressionally Directed Medical Research Programs","NCI NIH HHS"],"pagination":["493"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12899641"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(3)"],"pubmed_abstract":["Prostate cancer is the third-leading cause of cancer death in men. Prostate-specific membrane antigen (PSMA) is a robust biomarker that is expressed in approximately 80% of patients diagnosed with prostate cancer; several theranostic strategies have emerged based upon targeting this biomarker. This report describes a dimeric aptamer complex (DAC) which is selective for PSMA<sup>+</sup> cancer cells and is amenable to derivatization with additional diagnostic and therapeutic molecules. Confocal microscopy confirmed the selective nature of the DAC for PSMA<sup>+</sup> LNCAP tumor cells. In addition, the affinity of the DAC for the PSMA protein was determined to be 2.16 ± 0.15 nM using biolayer interferometry (BLI). In proof-of-principle studies, this DAC was biotinylated (BioDAC; A10), compl"],"journal":["Molecules (Basel, Switzerland)"],"pubmed_title":["Preclinical Evaluation of a Radiolabeled Anti-PSMA Dimeric Aptamer in a Murine Model of Human Prostate Cancer."],"pmcid":["PMC12899641"],"funding_grant_id":["R21-CA219899","W81XWH-19-1-0046","R21-CA227709"],"pubmed_authors":["Sinha A","Pandya DN","Eeka P","Wadas TJ","Boyacioglu O","Gmeiner WH"],"additional_accession":[]},"is_claimable":false,"name":"Preclinical Evaluation of a Radiolabeled Anti-PSMA Dimeric Aptamer in a Murine Model of Human Prostate Cancer.","description":"Prostate cancer is the third-leading cause of cancer death in men. Prostate-specific membrane antigen (PSMA) is a robust biomarker that is expressed in approximately 80% of patients diagnosed with prostate cancer; several theranostic strategies have emerged based upon targeting this biomarker. This report describes a dimeric aptamer complex (DAC) which is selective for PSMA<sup>+</sup> cancer cells and is amenable to derivatization with additional diagnostic and therapeutic molecules. Confocal microscopy confirmed the selective nature of the DAC for PSMA<sup>+</sup> LNCAP tumor cells. In addition, the affinity of the DAC for the PSMA protein was determined to be 2.16 ± 0.15 nM using biolayer interferometry (BLI). In proof-of-principle studies, this DAC was biotinylated (BioDAC; A10), compl","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-07-08T03:16:39.54Z","creation":"2026-07-08T03:08:39.87Z"},"accession":"S-EPMC12899641","cross_references":{"pubmed":["41683470"],"doi":["10.3390/molecules31030493"]}}